A specific sequence of therapies can improve outcomes for patients with some aggressive forms of lymphoma, according to a new study.
Reporting in the British Journal of Haematology, researchers report using a range of techniques to identify an alternative to chemotherapy for relapsed/refractory mature T and natural killer cell lymphomas (TNKL).
The study, led by a team from Massachusetts, USA, suggests using small molecule inhibitors as second-line treatment and epigenetic modifiers as third-line therapy.
The conclusions come from a retrospective analysis of the peripheral T cell lymphoma (PETAL) consortium.
The researchers used machine learning to compare 12 possible treatment paths for second- and third-line therapies. There were 540 p...
1 day ago
